News Releases
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
Jan 03, 2022
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Dec 07, 2021
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
Nov 12, 2021
Prometheus Biosciences to Present at Upcoming Investor Conferences
Nov 02, 2021
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
Oct 12, 2021
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
Aug 11, 2021
In Memoriam – Friend, Scientific Innovator, Advisor and Prometheus Biosciences’ Board Chair Dr. Tadataka Yamada Has Passed Away
Aug 05, 2021
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
Aug 02, 2021
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
Jul 19, 2021
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
Jul 15, 2021
Displaying 21 - 30 of 47